Afya: The Margin Is in Medicine, the Story Is Everywhere Else
A +6% revenue quarter and 44% EBITDA margin are the easy part — the hard part is a two-year wait for the digital segments to pay for themselves, and a December exam result that could reset 2027.
AFYA · Earnings Call · 2026-11-12
Undergrad pays the bills; the small segments absorb the spend
Afya's third quarter of 2026 was, on the surface, unremarkable in the best way. Revenue rose 6% year-over-year to BRL 985 million; adjusted EBITDA rose 9% to BRL 434 million; the margin expanded 100 basis points to 44%. Across nine months, revenue reached BRL 2,970 million (+7%), EBITDA BRL 1,352 million (+5%) at a 45.5% margin, and net income BRL 634 million (+7%), with EPS up 9% to BRL 6.98 thanks to the buyback. Cash conversion held near 100% — 99.5% — with BRL 629 million of free cash flow to equity. The composition is what matters. Undergraduate revenue was BRL 2,642 million of the nine-month total — roughly 89% — and 85% of that came from medicine, 93% from health-related courses. Medical seats grew 5% to 3,785, the medical student base crossed 26,000 (+3%), and net average ticket rose 4% to BRL 9,466. average tickets in the core franchise are still moving with, or slightly ahead of, inflation. Meanwhile Continuing Education revenue was BRL 209 million, up just 1%, and Medical Practice Solutions was BRL 128 million, flat. Both were deliberately pushed into an investment cycle late last year — product build, technology, sales teams — and both compressed gross margin this quarter. Consolidated margin expansion came entirely from undergrad, where the company is diluting fixed costs, packing more students per class and combining health disciplines across programs to reduce faculty cost. So the optics are flattered by the 89% that is working. The story is in the 11% that is being rebuilt.A two-year wait, stated with unusual honesty
Flavio Yoshida of Bank of America asked the right question: the student base keeps growing but revenue per student does not, so when does monetization catch up? Virgilio Gibbon did not sugarcoat it:He then dated the recovery to 2027-2028 for continuing education revenue per student to stabilize in the low single digits. That is a two-year wait in a company that the market has historically valued as a maturing med-school roll-up, not a platform transition. The volume is genuinely there. The student base in continuing education grew 10% over nine months; other B2P and B2B offerings grew 17%; the undergraduate journey grew 2%; and the residency segment was down 4% year-over-year but up 4% sequentially on seasonality. In Medical Practice Solutions, active payers rose 2% to roughly 206,000, with clinical management payers up 20% to 52,000 on iClinic penetration, while monthly active users slipped 4%. That user decline is not new. The Q2 call attributed it to AI tools pressuring Whitebook's payer count — the decline on Whitebook was flagged explicitly in August — and to a deliberate repricing of the freemium/premium mix. Management is now investing to embed AI features and rebuild engagement, which is precisely the investment cycle that is suppressing segment margins today.We are growing faster the student base... the mix effect here is that we have much more student applying for short duration programs, more related to procedure, new technicals for some specialties. And that -- the consequence direction of that is that the revenue does not come because the tuition is much lower.